Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Soligenix, Inc. logo — We are a late-stage biopharmaceutical company focused on dev...

Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases

Founded 1987 United States Princeton, United States 27 employees Post-IPO Equity Total: $55.97M Biopharma, Biotechnology +1

General Information

Company Name Soligenix, Inc.
Founded Year 1987
Location United States Princeton, United States
Founders / Decision Makers
Team member Team member
Employees 27
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Soligenix, Inc.. To contact Soligenix, Inc., visit soligenix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Soligenix, Inc. compare?

A PDF of Soligenix, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Soligenix, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Soligenix, Inc.

Soligenix: A late-stage biopharmaceutical company, was founded in 1987. The company's slogan emphasizes its focus on developing and commercializing products to treat rare diseases. Soligenix's Specialized BioTherapeutics business segment is currently working on HyBryte™ (SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), with plans for regulatory approval and commercialization in the U.S. Additionally, the company is developing expansion programs for synthetic hypericin into psoriasis, an innate defense regulator technology for inflammatory diseases, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention and treatment of gastrointestinal disorders, including pediatric Crohn's disease. In the Public Health Solutions business segment, Soligenix is actively developing RiVax®, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses, coronaviruses including COVID-19, and a therapeutic candidate for antibiotic-resistant and emerging infectious diseases. These programs have received support from government grants and contract funding. Notably, the company secured a $4.75M post-IPO equity investment on 18 April 2024. With a strong focus on addressing unmet medical needs, Soligenix is leveraging its expertise in biopharma, biotechnology, and healthcare from its headquarters in the United States. The company's diverse portfolio and government support in the development of crucial health solutions position it as a compelling investment opportunity in the biopharmaceutical industry.

Business keywords: biopharmaceutical company, rare diseases, photodynamic therapy, vaccine development, oncology, gastrointestinal disorders, innovative therapies, biodefense, infectious diseases, drug development, clinical research, regulatory approval, government funding, late-stage development

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $4.75M -
18 Apr 2024
Post IPO Equity $8.50M -
05 May 2023
Post IPO Debt $1.20M 1
NJEDA
NJEDA
15 Nov 2022
Grant $2.60M 1
U.S. Food and Drug Administration
06 Sep 2022
Grant $1.40M 2
NJEDA
NJEDA, Cabinet Office - GOV.UK
19 Apr 2022
Grant $1.50M 1
National Institutes of Health
28 Dec 2020
Grant $1.50M 1
National Institutes of Health
18 Sep 2017
Post IPO Equity $2.50M -
14 Aug 2017
Grant $634.00K 2
National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority (BARDA)
25 Jul 2016
Venture Round $10.00M 1
Kodiak Capital Group
Kodiak Capital Group
03 Aug 2015

View All 15 Funding Rounds

Soligenix, Inc. Alternatives & Competitors

View All Alternatives
Soligenix, Inc. vs
X4 Pharmaceuticals
X4 Pharmaceuticals United States

Enabling a better future for people with rare immune disorders

Post-IPO Debt
137 employees
Biotechnology, Health Care
Compare Soligenix, Inc. vs X4 Pharmaceuticals
Soligenix, Inc. vs
Forma Therapeutics
Forma Therapeutics United States

Dedicated to transforming the lives of patients with rare hematologic diseases and cancers.

Series D
159 employees
Biotechnology, Health Care
Compare Soligenix, Inc. vs Forma Therapeutics
Soligenix, Inc. vs
Rezolute, Inc.
Rezolute, Inc. United States

Rezolute is developing transformative therapeutics for rare and metabolic diseases.

Post-IPO Equity
66 employees
Biotechnology, Health Care
View all alternatives

FAQ About Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases
Soligenix, Inc. was founded in 1987.
Soligenix, Inc. is headquartered in Princeton, United States.
Soligenix, Inc. operates in Biopharma, Biotechnology and Health Care. Its work centres on biopharmaceutical company, rare diseases, photodynamic therapy and vaccine development.
Soligenix, Inc. has approximately 27 employees.
Soligenix, Inc. has completed 15 funding rounds, raising a total of $55.97M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Soligenix, Inc. include X4 Pharmaceuticals, Forma Therapeutics, Rezolute, Inc., Eloxx Pharmaceuticals, Tetralogic Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Soligenix, Inc. and X4 Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Soligenix, Inc., https://bouncewatch.com/company/soligenix, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes